Company intelligence / Profile preview
GeneToBe
Ann Arbor, Michigan, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
GeneToBe is developing next-generation genetic therapies using siRNA-based gene silencing and the proprietary MiCas9 CRISPR/Cas9 platform, with programs targeting Cystic Fibrosis, Usher Syndrome, and MASH. The company utilizes genetically-modified rabbit models for preclinical testing, but no clinical results have been reported as of 2025.
- Therapeutic areas
- PulmonologyMetabolic DisordersRare Diseases
- Modalities
- Small interfering RNACRISPR-based therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on GeneToBe.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeneToBe.